Hope for kids with tough cancer: new combo trial launches
NCT ID NCT07261241
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests three different combinations of a radioactive drug (131I-MIBG) with other medicines (vorinostat and/or dinutuximab) in children and young adults with relapsed or refractory neuroblastoma. About 118 participants will be randomly assigned to one of three treatment arms to see which combination shrinks tumors best. The goal is to find a more effective treatment for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
131I-MIBG (radioactive drug) combined with vorinostat and/or dinutuximab
What this could lead to
If successful, this trial could identify a more effective combination therapy for relapsed or refractory neuroblastoma, potentially improving tumor response rates.
What could go wrong
This is a phase 2 trial with only 118 participants, so results are preliminary. The treatments involve significant side effects, including high-grade toxicities, and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
C.S Mott Children's Hospital
Ann Arbor, Michigan, 48109, United States
-
Children Hospital of Colorado
Aurora, Colorado, 80045, United States
-
Children's Healthcare of Atlanta
Atlanta, Georgia, 30322, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027-0700, United States
-
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington, 98105, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104-4318, United States
-
Children's Memorial Hospital - Chicago
Chicago, Illinois, 60614, United States
-
Childrens Hospital Boston, Dana-Farber Cancer Institute.
Boston, Massachusetts, 02115, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229-3039, United States
-
Cook Children's Medical Center - Fort Worth
Fort Worth, Texas, 76104, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Contact Email: •••••@•••••
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94143, United States
-
University of Texas Southwestern
Dallas, Texas, 75235, United States
Contact Email: •••••@•••••